111 related articles for article (PubMed ID: 22412137)
1. Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer.
Laurent-Puig P; Manceau G; Zucman-Rossi J; Blons H
J Clin Oncol; 2012 May; 30(13):1550-2. PubMed ID: 22412137
[No Abstract] [Full Text] [Related]
2. Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends.
Katsios C; Ziogas DE; Roukos DH; Baltogiannis G
Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):5-8. PubMed ID: 23265143
[No Abstract] [Full Text] [Related]
3. Maintenance therapy in metastatic colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2014 Jun; 12(6):388-90. PubMed ID: 25003569
[No Abstract] [Full Text] [Related]
4. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
5. HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.
Boidot R; Chevrier S; Julie V; Ladoire S; Ghiringhelli F
Int J Colorectal Dis; 2016 Jun; 31(6):1245-6. PubMed ID: 26561417
[No Abstract] [Full Text] [Related]
6. Epidermal growth factor receptor inhibitors and colorectal cancer.
Meyerhardt JA; Fuchs CS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):35-8. PubMed ID: 15685832
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
10. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Abdel-Rahman O
Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
[TBL] [Abstract][Full Text] [Related]
11. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
Chu E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
[No Abstract] [Full Text] [Related]
12. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
14. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Normanno N; Tejpar S; Ciardiello F
J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
[No Abstract] [Full Text] [Related]
15. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
Chong G; Cunningham D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.
Cheng L; Ren W; Xie L; Li M; Liu J; Hu J; Liu BR; Qian XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):1-13. PubMed ID: 24916545
[TBL] [Abstract][Full Text] [Related]
17. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
18. Targeted therapy for advanced colorectal cancer--more is not always better.
Mayer RJ
N Engl J Med; 2009 Feb; 360(6):623-5. PubMed ID: 19196680
[No Abstract] [Full Text] [Related]
19. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenesis drug promising for metastatic colorectal cancer.
McCarthy M
Lancet; 2003 Jun; 361(9373):1959. PubMed ID: 12801743
[No Abstract] [Full Text] [Related]
[Next] [New Search]